GFP/Luc Reporter Cell Line - Calu-1

The Calu-1 cell line is a widely utilized human model of non-small cell lung cancer (NSCLC), originally established from a pleural effusion metastasis of a patient with epidermoid (squamous cell) carcinoma of the lung. It is highly valued in thoracic oncology for its aggressive growth profile and serves as a robust preclinical tool for investigating the complex biology and underlying molecular mechanisms driving squamous cell lung malignancies. The GFP/Luc Reporter Cell Line - Calu-1 is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both Green Fluorescent Protein (GFP) and firefly luciferase (Luc). This advanced dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental morphological characteristics, intrinsic biological properties, or the inherent tumorigenic capacity of the original parental Calu-1 cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the Calu-1 model for translational respiratory oncology. For in vitro studies, the distinct GFP expression allows researchers to easily visualize cellular dynamics, accurately quantify rapid proliferation rates, and seamlessly isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase activity serves as the optimal foundation for non-invasive, longitudinal tracking of primary tumor progression and metastatic dissemination through bioluminescence imaging (BLI). Because it is a human-derived cell line, the Calu-1-GFP/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish highly reliable subcutaneous xenografts or clinically relevant orthotopic pulmonary models. This specialized reporter line represents an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of novel chemotherapeutic regimens, targeted pharmacological compounds, and emerging biotherapeutics aimed at refractory lung cancers, facilitating the real-time, accurate quantification of localized tumor burden in living subjects.